Statistics from Altmetric.com
Pritelivir for herpes simplex virus
Researchers in the USA have been trialling a new drug pritelivir in a phase II trial reported in this paper1 by Wald et al. Pritelivir is a new herpes simplex virus (HSV) helicase-primase inhibitor which reduces genital shedding and HSV lesions. In this study, pritelivir and valaciclovir were compared in a randomised double-blinded crossover trial at four centres in the USA and the study recruited 92 participants (male and female) who had a history of four to nine outbreaks of HSV-2 per year. Participants were asked to undertake genital swabs four times a day and were randomised to receive pritelivir for 28 days followed by a washout period of 28 days and then 28 days of valaciclovir, or vice versa with a primary end point of genital shedding. Fifty six out of the 91 randomised participants (63% of which were female) completed the trial, and genital shedding was seen in 2.4% vs 5.3% patients in the pritelivir versus valaciclovir arms with a relative risk (RR) …
Contributors SH chose the papers for review and wrote the manuscript.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.